Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.58 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.58 |
| ▸ | CTSB | P07858 | 4/20 | 0.56 |
| ▸ | CTSS | P25774 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24960978 | 1.00 | CTSL (0.58) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL24960495 | 0.94 | CTSL (0.59) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL26535248 | 0.94 | CTSL (0.59) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL24960975 | 0.92 | CTSL (0.61) | CTSLCAPN1CTSB | |
| SCHEMBL24961103 | 0.92 | CTSL (0.54) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL14215321 | 0.92 | CTSL (0.54) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL25284018 | 0.92 | CTSL (0.61) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL25243876 | 0.92 | CTSL (0.61) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL24961100 | 0.92 | CTSL (0.56) | CTSLCAPN1CTSBCTSSCTSK | |
| SCHEMBL24690933 | 0.91 | CTSL (0.61) | CTSLCAPN1CTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462594-B2 | Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-12-09 | — | — | US | disclosed |
| US-7462594-B2 | Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-12-09 | — | — | US | disclosed |
| US-20080125375-A1 | PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-05-29 | — | — | US | disclosed |
| US-7304088-B2 | Peptide like compounds for treating coronavirus or hepatitis C virus; severe acute respiratory distress syndrome | TAIGEN BIOTECHNOLOGY (TW) | 2007-12-04 | — | — | US | disclosed |
| US-7304088-B2 | Peptide like compounds for treating coronavirus or hepatitis C virus; severe acute respiratory distress syndrome | TAIGEN BIOTECHNOLOGY (TW) | 2007-12-04 | — | — | US | disclosed |
| US-20050143320-A1 | Protease inhibitors | TAIGEN BIOTECHNOLOGY | 2005-06-30 | — | — | US | disclosed |
| US-20050143320-A1 | Protease inhibitors | TAIGEN BIOTECHNOLOGY | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143320-A1 | Protease inhibitors | PREP, SPINT2, SERPINB1 | CTSL 33/4885CAPN1 710/4885CTSB 39/4885 |
| US-20080125375-A1 | PROTEASE INHIBITORS | PREP, SERPINB1, SPINT2 | CTSL 35/4885CAPN1 498/4885CTSB 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.